- Home
- MDCX vs FGEN Comparison
MDCX vs FGEN Comparison
Compare MDCX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- FGEN
- Stock Information
- Founded
- MDCX 2008
- FGEN 1993
- Country
- MDCX Canada
- FGEN United States
- Employees
- MDCX N/A
- FGEN N/A
- Industry
- MDCX
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- FGEN Health Care
- Exchange
- MDCX Nasdaq
- FGEN Nasdaq
- Market Cap
- MDCX 36.2M
- FGEN 38.4M
- IPO Year
- MDCX N/A
- FGEN 2014
- Fundamental
- Price
- MDCX $1.94
- FGEN $11.83
- Analyst Decision
- MDCX Strong Buy
- FGEN Strong Buy
- Analyst Count
- MDCX 2
- FGEN 2
- Target Price
- MDCX $23.50
- FGEN $146.50
- AVG Volume (30 Days)
- MDCX 408.7K
- FGEN 70.3K
- Earning Date
- MDCX 08-11-2025
- FGEN 08-11-2025
- Dividend Yield
- MDCX N/A
- FGEN N/A
- EPS Growth
- MDCX N/A
- FGEN N/A
- EPS
- MDCX N/A
- FGEN N/A
- Revenue
- MDCX N/A
- FGEN $7,346,000.00
- Revenue This Year
- MDCX N/A
- FGEN N/A
- Revenue Next Year
- MDCX N/A
- FGEN N/A
- P/E Ratio
- MDCX N/A
- FGEN N/A
- Revenue Growth
- MDCX N/A
- FGEN N/A
- 52 Week Low
- MDCX $1.80
- FGEN $4.50
- 52 Week High
- MDCX $8.94
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- MDCX 38.69
- FGEN 71.07
- Support Level
- MDCX $1.88
- FGEN $10.10
- Resistance Level
- MDCX $2.27
- FGEN $11.37
- Average True Range (ATR)
- MDCX 0.26
- FGEN 0.85
- MACD
- MDCX 0.02
- FGEN 0.09
- Stochastic Oscillator
- MDCX 19.40
- FGEN 88.36
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.